About this trial
The 100-Year Human Aging Study is a prospective, pragmatic, observational trial enrolling participants across fixed clinical sites, mobile clinical sites, and an online participation pathway (current and future) to undergo comprehensive multi-system health screening and longitudinal follow-up until death. Participants are followed to determine whether measurements taken at enrollment and repeated across the lifespan - individually and in combination - predict all-cause mortality, cause-specific mortality, incident serious disease, and functional disability. The study is designed to generate the surrogate endpoint validation data that longevity medicine currently lacks.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age 18 years or older
Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative
Willing to participate in longitudinal follow-up
Disqualifiers
Age under 18 years
Trial population
Participants of all ages, health statuses, and demographic backgrounds presenting for comprehensive preventive health screening at fixed or mobile clinical sites. No exclusions based on health status, geographic location, language, or population group. Participants with limited decision-making capacity may be enrolled with consent from a legally authorized representative. The study actively seeks to enroll participants across the full human lifespan including older adults and centenarians.
Trial design
Cohort
Prospective
Treatments tested in this trial
Comprehensive Multi-System Clinical Screening
Diagnostic testComprehensive multi-system clinical screening battery including cardiopulmonary exercise testing, body composition assessment by DEXA, echocardiography, electrocardiography, spirometry, neurocognitive testing, sensory assessment, metabolic testing, physical examination, and detailed medical, social, occupational, and environmental history. Participants receive individualized clinical findings and investigational longevity constructs at the conclusion of screening.
Treatment groups
Trial outcomes
Primary outcomes
All-Cause Mortality
Vital status ascertained through longitudinal follow-up contact, mortality record linkage, and health data network linkage using probabilistic matching on name, date of birth, and address history.
Cause-Specific Mortality
Cause of death ascertained via death certificate and mortality record linkage.
Secondary outcomes
Cause-Specific Mortality Prediction Accuracy
Concordance between predicted cause of death profile generated at enrollment and actual cause of death ascertained at follow-up.
Incident Serious Adverse Health Events
New diagnosis of myocardial infarction, stroke, cancer, dementia, heart failure, atrial fibrillation, sepsis, venous thromboembolism, COPD, chronic hypoxia, or major fracture ascertained via periodic follow-up contact and health data network linkage.
Incident Chronic Disease
New diagnosis of type 2 diabetes, hypertension, COPD, chronic kidney disease, metabolic syndrome, or osteoporosis ascertained via self-report and health data network linkage.
Functional Independence and Disability Status
Activities of daily living, instrumental activities of daily living, and self-reported disability status ascertained via periodic health survey using validated open-source instruments. Higher composite scores indicate greater functional independence. Specific instruments will be selected prior to first follow-up contact and documented in the statistical analysis plan.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.